Takeda
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Phone Number
+81 332782111Website
www.takeda.com.peRevenue
<$5 MillionIndustry
About Takeda
Is Takeda your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Takeda launches new products
Check out if Takeda is spiking on competitors!
Check if Takeda has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Takeda recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Takeda
Website visits: Recent activity has been detected on your website
Takeda, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Takeda has new funding data
Click to see if Takeda had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Takeda
Find 2 more new buyers
Company Profile Activity
Activity Insights
Takeda is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Takeda is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Takeda.
Takeda Tech Stack
A closer look at the technologies used by Takeda
Takeda News & Media
Takeda, slimming down for 'new era,' plots 4500 layoffs in latest restructuring drive
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to shake off the generic-related declines that have plagued revenues in recent | Takeda's multiyear slim-down is expected to hit about 4,500 roles during the 2026 fiscal year, resulting in about 170 billion Japanese yen ($1.07 billion) in restructuring costs and some 100 billion yen ($633 million) in gross savings forTakeda's Next Wave of Drugs Has Investors Watching Closely
Takeda Pharmaceutical Company Ltd. (NYSE:TAK) reported fourth-quarter sales of $6.98 billion, or 1.094 trillion yen, missing Wall Street estimates of $7.05 billion. The Japanese drugmaker reported adjusted earnings of 28 cents per ADR (89 yen per share), beating analyst estimates of 21 cents per share. CFO Highlights Profitability, Cash Flow Focus Chief Financial Officer Milano Furuta said the company delivered "solid profit and cash flow through disciplined cost control" in fiscal 2025 despite
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenter... Read More